The review discusses innovative methods for diagnosing and treating cancers using radiolabeled regulatory peptides.
It highlights peptide receptor-targeted radionuclide therapy, which specifically targets cancer cells with high receptor expression while minimizing harm to normal tissues.
The paper emphasizes the importance of assessing treatment toxicity, radiation dosimetry, and the biological characteristics of the drugs to ensure an effective balance between clinical benefits and risks.